AU2001225816B2 - Therapeutic combination of amlodipine and benazepril - Google Patents

Therapeutic combination of amlodipine and benazepril Download PDF

Info

Publication number
AU2001225816B2
AU2001225816B2 AU2001225816A AU2001225816A AU2001225816B2 AU 2001225816 B2 AU2001225816 B2 AU 2001225816B2 AU 2001225816 A AU2001225816 A AU 2001225816A AU 2001225816 A AU2001225816 A AU 2001225816A AU 2001225816 B2 AU2001225816 B2 AU 2001225816B2
Authority
AU
Australia
Prior art keywords
benazepril
amlodipine
pharmaceutically acceptable
acceptable salt
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2001225816A
Other languages
English (en)
Other versions
AU2001225816A1 (en
Inventor
William Lionel Daley
Randy Lee Webb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21742073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2001225816(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2001225816A1 publication Critical patent/AU2001225816A1/en
Application granted granted Critical
Publication of AU2001225816B2 publication Critical patent/AU2001225816B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001225816A 2000-12-18 2000-12-18 Therapeutic combination of amlodipine and benazepril Ceased AU2001225816B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/034246 WO2002049645A1 (en) 2000-12-18 2000-12-18 Therapeutic combination of amlodipine and benazepril

Publications (2)

Publication Number Publication Date
AU2001225816A1 AU2001225816A1 (en) 2002-09-05
AU2001225816B2 true AU2001225816B2 (en) 2005-10-13

Family

ID=21742073

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2001225816A Ceased AU2001225816B2 (en) 2000-12-18 2000-12-18 Therapeutic combination of amlodipine and benazepril
AU2581601A Pending AU2581601A (en) 2000-12-18 2000-12-18 Therapeutic combination of amlodipine and benazepril
AU2002232620A Ceased AU2002232620B9 (en) 2000-12-18 2001-12-17 Therapeutic combination of amlodipine and benazepril/benazeprilat
AU3262002A Pending AU3262002A (en) 2000-12-18 2001-12-17 Therapeutic combination of amlodipine and benazepril/benazeprilat

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2581601A Pending AU2581601A (en) 2000-12-18 2000-12-18 Therapeutic combination of amlodipine and benazepril
AU2002232620A Ceased AU2002232620B9 (en) 2000-12-18 2001-12-17 Therapeutic combination of amlodipine and benazepril/benazeprilat
AU3262002A Pending AU3262002A (en) 2000-12-18 2001-12-17 Therapeutic combination of amlodipine and benazepril/benazeprilat

Country Status (26)

Country Link
EP (3) EP1365761A1 (cg-RX-API-DMAC10.html)
JP (3) JP2004516266A (cg-RX-API-DMAC10.html)
KR (3) KR20040007420A (cg-RX-API-DMAC10.html)
CN (2) CN1461218A (cg-RX-API-DMAC10.html)
AT (1) ATE338549T1 (cg-RX-API-DMAC10.html)
AU (4) AU2001225816B2 (cg-RX-API-DMAC10.html)
BR (2) BR0017386A (cg-RX-API-DMAC10.html)
CA (2) CA2432638A1 (cg-RX-API-DMAC10.html)
CY (1) CY1106275T1 (cg-RX-API-DMAC10.html)
CZ (2) CZ20031678A3 (cg-RX-API-DMAC10.html)
DE (1) DE60122928T2 (cg-RX-API-DMAC10.html)
DK (1) DK1345607T3 (cg-RX-API-DMAC10.html)
EC (1) ECSP034658A (cg-RX-API-DMAC10.html)
ES (1) ES2272565T3 (cg-RX-API-DMAC10.html)
HU (2) HUP0302455A3 (cg-RX-API-DMAC10.html)
IL (4) IL156136A0 (cg-RX-API-DMAC10.html)
MX (2) MXPA03005462A (cg-RX-API-DMAC10.html)
NO (2) NO20032766L (cg-RX-API-DMAC10.html)
NZ (1) NZ526467A (cg-RX-API-DMAC10.html)
PL (2) PL362252A1 (cg-RX-API-DMAC10.html)
PT (1) PT1345607E (cg-RX-API-DMAC10.html)
RU (1) RU2292206C2 (cg-RX-API-DMAC10.html)
SI (1) SI1345607T1 (cg-RX-API-DMAC10.html)
SK (2) SK7652003A3 (cg-RX-API-DMAC10.html)
WO (2) WO2002049645A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200304514B (cg-RX-API-DMAC10.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0214383A (pt) * 2001-11-23 2004-11-03 Solvay Pharm Gmbh Tratamento de hipertonia durante a fase aguda do ataque de apoplexia
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
CN1859913A (zh) 2003-04-25 2006-11-08 美国诺华卡迪亚公司 改善肾功能损伤个体多尿症的方法
KR20060120126A (ko) * 2003-10-20 2006-11-24 노파르티스 아게 심혈관계 이환상태를 감소시키기 위한 베나제프릴 및암로디핀
WO2005074927A1 (en) * 2004-02-09 2005-08-18 Novartis Ag Therapeutic combination of amlodipine and benazepril/ benazeprilat for the treatment of hypertension
WO2005079772A2 (en) * 2004-02-18 2005-09-01 Sepracor Inc. Combination of (s)-amlodipine and an ace inhibitor, and methods for reducing hypertension
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
US20080268049A1 (en) * 2005-02-11 2008-10-30 Dhaliwal Mona Stable Solid Dosage Forms of Amlodipine and Benazepril
WO2006092732A2 (en) * 2005-03-04 2006-09-08 Aurobindo Pharma Ltd Stable solid dosage form of antihypertensive agent
MX2007011119A (es) 2005-03-15 2007-11-14 Lupin Ltd Composiciones farmaceuticas de amlodipino y benazepril.
EP1930008A1 (en) * 2005-09-28 2008-06-11 Teva Pharmaceutical Industries Ltd Sable composition of benazepril hydrochloride
US8158146B2 (en) 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
JP2009508948A (ja) * 2005-09-28 2009-03-05 テバ ファーマシューティカル インダストリーズ リミティド アムロジピンベシレート及びベナゼプリル塩酸塩の安定した組合わせ
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
IT1398168B1 (it) * 2010-02-16 2013-02-14 Chiesi Farma Spa Uso di ingredienti attivi in combinazione per il trattamento delle complicanze del diabete.
WO2011161223A2 (en) 2010-06-23 2011-12-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts
CN102389431A (zh) * 2011-09-28 2012-03-28 济南龙华医药技术有限公司 一种含有盐酸贝尼地平和盐酸贝那普利的复方制剂及其应用
RU2014129508A (ru) * 2011-12-21 2016-02-10 Новартис Тиргезундхайт АГ Новая комбинация
US10398705B2 (en) 2012-03-15 2019-09-03 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
JP2015529206A (ja) * 2012-08-25 2015-10-05 ザ・ジョンズ・ホプキンス・ユニバーシティ Ｇａｐｄｈカスケードインヒビター化合物ならびに使用の方法および精神病を含むストレス誘導障害の処置
AU2014292086B2 (en) 2013-07-19 2019-08-08 Boehringer Ingelheim Vetmedica Gmbh Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
MX375936B (es) 2013-12-04 2025-03-07 Boehringer Ingelheim Vetmedica Gmbh Composiciones farmaceuticas mejoradas de pimobendan.
EP3434284A4 (en) * 2016-03-24 2019-11-13 Daiichi Sankyo Company, Limited MEDICINE FOR THE TREATMENT OF KIDNEY DISEASE
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
PL3541807T3 (pl) 2016-11-16 2022-01-17 H. Lundbeck A/S Krystaliczna postać inhibitora magl
CA3043609A1 (en) 2016-11-16 2018-05-24 Abide Therapeutics, Inc. Pharmaceutical formulations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0795327A1 (en) * 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162802A (en) * 1992-03-10 2000-12-19 Papa; Joseph Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor
EP0804229B1 (en) * 1995-03-16 2003-03-26 Pfizer Inc. Use of amlodipine, a salt thereof or felodipin in combination with an ace inhibitor in the manufacture of a medicament for the treatment of nonischemic congestive heart failure
KR19980703647A (ko) * 1995-04-07 1998-12-05 베르너발데크 베나제프릴 또는 베나제프릴라트 및 발사르탄을 함유하는조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0795327A1 (en) * 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cardiovascular Reviews and reports, vol. 20, 7, 1999, pp 368-374 *
Clin. Therap. Vol. 18, 1996, pp 1213-1224 *

Also Published As

Publication number Publication date
SK7642003A3 (en) 2003-11-04
NO20032766D0 (no) 2003-06-17
AU2581601A (en) 2002-07-01
CA2432638A1 (en) 2002-06-27
ZA200304514B (en) 2004-05-10
DE60122928T2 (de) 2007-09-06
KR20090033914A (ko) 2009-04-06
HK1059566A1 (en) 2004-07-09
SI1345607T1 (sl) 2007-02-28
ES2272565T3 (es) 2007-05-01
IL156267A0 (en) 2004-01-04
JP2010043111A (ja) 2010-02-25
NO20032766L (no) 2003-08-14
KR20040007420A (ko) 2004-01-24
MXPA03005462A (es) 2003-09-25
DK1345607T3 (da) 2006-12-27
CA2432282A1 (en) 2002-06-27
CN1461218A (zh) 2003-12-10
IL190801A0 (en) 2008-11-03
JP2004519440A (ja) 2004-07-02
WO2002049646A1 (en) 2002-06-27
BR0116228A (pt) 2003-12-30
ATE338549T1 (de) 2006-09-15
SK7652003A3 (en) 2003-12-02
WO2002049645A1 (en) 2002-06-27
JP2004516266A (ja) 2004-06-03
CZ20031678A3 (cs) 2003-10-15
CN1481241A (zh) 2004-03-10
IL156136A0 (en) 2003-12-23
MXPA03005463A (es) 2003-09-25
PT1345607E (pt) 2007-01-31
CY1106275T1 (el) 2011-10-12
EP1365761A1 (en) 2003-12-03
HUP0302456A3 (en) 2004-05-28
ECSP034658A (es) 2003-07-25
AU2002232620B2 (en) 2005-11-03
BR0017386A (pt) 2004-01-13
EP1674099A1 (en) 2006-06-28
KR20030061840A (ko) 2003-07-22
CZ20031677A3 (cs) 2003-10-15
HUP0302455A3 (en) 2005-05-30
AU3262002A (en) 2002-07-01
PL360989A1 (en) 2004-09-20
EP1345607B1 (en) 2006-09-06
HUP0302455A2 (hu) 2003-11-28
RU2003121019A (ru) 2005-01-20
AU2002232620B9 (en) 2005-11-24
EP1345607A1 (en) 2003-09-24
NO20032765D0 (no) 2003-06-17
NZ526467A (en) 2005-04-29
PL362252A1 (en) 2004-10-18
CZ301424B6 (cs) 2010-02-24
DE60122928D1 (de) 2006-10-19
IL190802A0 (en) 2008-11-03
NO20032765L (no) 2003-08-14
RU2292206C2 (ru) 2007-01-27
HUP0302456A2 (hu) 2003-11-28

Similar Documents

Publication Publication Date Title
AU2002232620B9 (en) Therapeutic combination of amlodipine and benazepril/benazeprilat
CZ20023381A3 (cs) Kombinované farmaceutické prostředky obsahující antagonistu AT1-receptoru nebo/a inhibitor HMG-CoA reduktázy nebo/a ACE inhibitor
CZ292224B6 (cs) Farmaceutický přípravek, způsob jeho výroby a použití
US6162802A (en) Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor
AU2439700A (en) Use of angiotensin ii receptor antagonists for treating acute myocardial infarction
WO2009010810A2 (en) Cardiovascular combinations comprising ace and hmg-co-a inhibitors
RU2182002C2 (ru) Композиция с фиксированной дозой ингибитора ангиотензин-превращающего фермента и антагониста кальциевых каналов, способ ее изготовления и применение для лечения сердечно-сосудистых заболеваний
US20100196467A1 (en) Therapeutic combination of amlodipine and benazepril/benazeprilat
US20040048905A1 (en) Therapeutic combination of amlodipine and benazepril
NZ526385A (en) High dose therapeutic combination of amlodipine and benazepril
ZA200304330B (en) Therapeutic combination of amlodipine and benazepril.
HK1094147A (en) Therapeutic combination of amlodipine and benazepril/benazeprilat
HK1059566B (en) Therapeutic combination of amlodipine and benazepril/benazeprilat
KR102066832B1 (ko) 텔미사르탄 또는 그의 약제학적으로 허용가능한 염을 포함하는 인습성 및 용출률이 향상된 제제
ITTO960379A1 (it) Composizione farmaceutica per malattie cardiovascolari e renali.
AU2005209657A1 (en) Combination of at least two compounds selected from an AT1-Receptor antagonist or an ACE inhibitor or a HMG-CO-A reductase inhibitor group

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired